The Dana-Farber Cancer Institute Cancer Target Discovery and Development Center

丹娜—法伯癌症研究所癌症靶标发现和开发中心

基本信息

  • 批准号:
    9362809
  • 负责人:
  • 金额:
    $ 102.74万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2013
  • 资助国家:
    美国
  • 起止时间:
    2013-05-01 至 2022-07-31
  • 项目状态:
    已结题

项目摘要

Abstract International efforts to characterize cancer genomes now provide us with an initial view of the mutations and copy number alterations that occur in human cancers. These efforts have expanded our knowledge of known oncogenic pathways and have identified new classes of oncogenes and tumor suppressor genes. However, it is now also clear that most epithelial cancers harbor hundreds of genetic alterations as a consequence of genomic instability, which complicates efforts to identify mutations critical for tumor maintenance and drives tumor heterogeneity. Moreover, it remains unclear which of these alterations confers on the tumor cell the ability to evade the immune system. The emerging clinical success of checkpoint blockade is tempered by the observation that most patients do not respond to immunotherapy. New immunotherapy targets are needed to improve tumor responses and guide rational combination immunotherapy to overcome resistance. Identifying genes that are essential for tumor survival and immune evasion will accelerate the development of new molecularly targeted therapeutics. Over the past several years, we have developed and deployed high throughput genetic and bioinformatics approaches to identify and credential cancer targets. Specifically, we have performed genome scale loss of function and gain of function screens in large sets of human cancer cell lines and patient-derived models and have identified new oncogenes and synthetic lethal interactions. The scale of these experiments has allowed us to overcome the inherent heterogeneity of cancers and to classify cancer dependencies and their context, which is essential for the initiation of drug discovery efforts. In this application, we propose to use these studies as a foundation for a new Dana-Farber Cancer Institute CTD2 Center. This Center will focus on the identification of and credentialing cancer targets, developing the means to rationally define combination therapies, and the identification of genes that modulate the response to immunotherapeutics, all through the use of novel in vitro and in vivo HT genetic and bioinformatic approaches. We will continue to make the outputs of these studies readily available to the scientific community and to participate in CTD2 Network activities. We anticipate that this Center will provide the cancer research community with information that will facilitate the prioritization of targets based on both genomic and functional evidence, inform the most appropriate genetic context for downstream mechanistic studies and facilitate the translation of this information into therapeutics and diagnostics.
摘要 国际上对癌症基因组特征的研究现在为我们提供了突变的初步看法, 发生在人类癌症中的拷贝数改变。这些努力扩大了我们对已知的 致癌途径,并确定了新的致癌基因和肿瘤抑制基因的类别。但 现在也很清楚,大多数上皮癌都有数百种遗传变异, 基因组不稳定性,这使得识别对肿瘤维持和驱动至关重要的突变的努力变得复杂。 肿瘤异质性此外,尚不清楚这些改变中的哪一个赋予肿瘤细胞以免疫抑制作用。 逃避免疫系统的能力。检查点阻断的临床成功受到以下因素的影响: 观察到大多数患者对免疫疗法没有反应。需要新的免疫治疗靶点, 提高肿瘤应答,指导合理联合免疫治疗克服耐药性。识别 对于肿瘤生存和免疫逃避至关重要的基因将加速新的肿瘤细胞的发展。 分子靶向治疗 在过去的几年里,我们已经开发和部署了高通量遗传和 生物信息学方法来识别和认证癌症靶点。具体来说,我们已经进行了基因组 在大量的人癌细胞系和患者来源的肿瘤细胞系中进行功能丧失和功能获得筛选 模型,并确定了新的致癌基因和合成致命的相互作用。这些实验的规模 使我们能够克服癌症固有的异质性,并对癌症依赖性进行分类, 他们的背景,这是至关重要的药物发现工作的启动。 在本申请中,我们建议使用这些研究作为一个新的丹娜-法伯癌症的基础 CTD 2中心。该中心将专注于癌症靶点的识别和认证, 开发合理定义联合治疗的方法,并鉴定调节 对免疫治疗剂的反应,所有这些都是通过使用新的体外和体内HT遗传和 生物信息学方法我们会继续把这些研究的结果, 科学界和参加CTD 2网络的活动。我们预计,该中心将提供 癌症研究界的信息,将有助于优先考虑的基础上, 基因组和功能证据,为下游机制提供最合适的遗传背景 研究,并促进这些信息转化为治疗和诊断。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

William C. Hahn其他文献

SV40 small T antigen and PP2A phosphatase in cell transformation
  • DOI:
    10.1007/s10555-008-9116-0
  • 发表时间:
    2008-01-23
  • 期刊:
  • 影响因子:
    8.700
  • 作者:
    Anna A. Sablina;William C. Hahn
  • 通讯作者:
    William C. Hahn
A compendium of Amplification-Related Gain Of Sensitivity genes in human cancer
人类癌症中与扩增相关的敏感性增益基因纲要
  • DOI:
    10.1038/s41467-025-56301-2
  • 发表时间:
    2025-01-27
  • 期刊:
  • 影响因子:
    15.700
  • 作者:
    Veronica Rendo;Michael Schubert;Nicholas Khuu;Maria F. Suarez Peredo Rodriguez;Declan Whyte;Xiao Ling;Anouk van den Brink;Kaimeng Huang;Michelle Swift;Yizhou He;Johanna Zerbib;Ross Smith;Jonne Raaijmakers;Pratiti Bandopadhayay;Lillian M. Guenther;Justin H. Hwang;Amanda Iniguez;Susan Moody;Ji-Heui Seo;Elizabeth H. Stover;Levi Garraway;William C. Hahn;Kimberly Stegmaier;René H. Medema;Dipanjan Chowdhury;Maria Colomé-Tatché;Uri Ben-David;Rameen Beroukhim;Floris Foijer
  • 通讯作者:
    Floris Foijer
The present and future of the Cancer Dependency Map
癌症依赖图谱的现在与未来
  • DOI:
    10.1038/s41568-024-00763-x
  • 发表时间:
    2024-10-28
  • 期刊:
  • 影响因子:
    66.800
  • 作者:
    Rand Arafeh;Tsukasa Shibue;Joshua M. Dempster;William C. Hahn;Francisca Vazquez
  • 通讯作者:
    Francisca Vazquez
Developing a library of authenticated Traditional Chinese Medicinal (TCM) plants for systematic biol
开发经过认证的中药 (TCM) 植物库,用于系统生物分析
  • DOI:
  • 发表时间:
    2011
  • 期刊:
  • 影响因子:
    0
  • 作者:
    David Eisenberg;Eric S. J. Harris;Bruce A. Littlefield;Shugeng Cao;Jane A. Craycroft;Robert Scholten;Peter E. Bayliss;Yanling Fu;Wenquan Wang;Yan;Zhongzhen Zhao;Hubiao Chen;Yong Liu;Ted J. Kaptchuk;William C. Hahn;Xiaoxin Wang;Thomas M. Roberts;C. Shamu;Jon Clardy
  • 通讯作者:
    Jon Clardy
CDK8 is a colorectal cancer oncogene that regulates β-catenin activity
CDK8 是一种调节β-连环蛋白活性的结直肠癌致癌基因
  • DOI:
    10.1038/nature07179
  • 发表时间:
    2008-09-14
  • 期刊:
  • 影响因子:
    48.500
  • 作者:
    Ron Firestein;Adam J. Bass;So Young Kim;Ian F. Dunn;Serena J. Silver;Isil Guney;Ellen Freed;Azra H. Ligon;Natalie Vena;Shuji Ogino;Milan G. Chheda;Pablo Tamayo;Stephen Finn;Yashaswi Shrestha;Jesse S. Boehm;Supriya Jain;Emeric Bojarski;Craig Mermel;Jordi Barretina;Jennifer A. Chan;Jose Baselga;Josep Tabernero;David E. Root;Charles S. Fuchs;Massimo Loda;Ramesh A. Shivdasani;Matthew Meyerson;William C. Hahn
  • 通讯作者:
    William C. Hahn

William C. Hahn的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('William C. Hahn', 18)}}的其他基金

Development of p300/CBP histone acetyltransferase inhibitors for oncogene-driven cancers
开发用于癌基因驱动癌症的 p300/CBP 组蛋白乙酰转移酶抑制剂
  • 批准号:
    10627744
  • 财政年份:
    2022
  • 资助金额:
    $ 102.74万
  • 项目类别:
Novel genetic dependencies in VRK2 methylated glioblastoma multiforme
VRK2甲基化多形性胶质母细胞瘤的新遗传依赖性
  • 批准号:
    10046375
  • 财政年份:
    2020
  • 资助金额:
    $ 102.74万
  • 项目类别:
Development and implementation of multiplex methods to understand the biology and heterogeneity of patient-derived cancer models
开发和实施多重方法来了解源自患者的癌症模型的生物学和异质性
  • 批准号:
    10004385
  • 财政年份:
    2020
  • 资助金额:
    $ 102.74万
  • 项目类别:
Systematic interrogation of the pancreatic cancer microenvironment in patient-derived specimens
系统研究患者来源标本中的胰腺癌微环境
  • 批准号:
    10250566
  • 财政年份:
    2017
  • 资助金额:
    $ 102.74万
  • 项目类别:
PROJECT 4: Interrogating PP2A Signaling in Human Cancers
项目 4:探究人类癌症中的 PP2A 信号传导
  • 批准号:
    9981674
  • 财政年份:
    2017
  • 资助金额:
    $ 102.74万
  • 项目类别:
Systematic interrogation of the pancreatic cancer microenvironment in patient-derived specimens
系统研究患者来源标本中的胰腺癌微环境
  • 批准号:
    10242454
  • 财政年份:
    2017
  • 资助金额:
    $ 102.74万
  • 项目类别:
Systematic identification of oncogenic KRAS synthetic lethal interactions
系统鉴定致癌 KRAS 合成致死相互作用
  • 批准号:
    9330127
  • 财政年份:
    2015
  • 资助金额:
    $ 102.74万
  • 项目类别:
Systematic identification of oncogenic KRAS synthetic lethal interactions
系统鉴定致癌 KRAS 合成致死相互作用
  • 批准号:
    9150537
  • 财政年份:
    2015
  • 资助金额:
    $ 102.74万
  • 项目类别:
The Dana-Farber Cancer Institute Cancer Target Discovery and Development Center
丹娜—法伯癌症研究所癌症靶标发现和开发中心
  • 批准号:
    9979771
  • 财政年份:
    2013
  • 资助金额:
    $ 102.74万
  • 项目类别:
Identification of TBK1 inhibitors in KRAS-dependent lung cancer
KRAS 依赖性肺癌中 TBK1 抑制剂的鉴定
  • 批准号:
    8237125
  • 财政年份:
    2012
  • 资助金额:
    $ 102.74万
  • 项目类别:

相似海外基金

Defining the biological boundaries to sustain extant life on Mars
定义维持火星现存生命的生物边界
  • 批准号:
    DP240102658
  • 财政年份:
    2024
  • 资助金额:
    $ 102.74万
  • 项目类别:
    Discovery Projects
Advanced Multiscale Biological Imaging using European Infrastructures
利用欧洲基础设施进行先进的多尺度生物成像
  • 批准号:
    EP/Y036654/1
  • 财政年份:
    2024
  • 资助金额:
    $ 102.74万
  • 项目类别:
    Research Grant
Open Access Block Award 2024 - Marine Biological Association
2024 年开放获取区块奖 - 海洋生物学协会
  • 批准号:
    EP/Z532538/1
  • 财政年份:
    2024
  • 资助金额:
    $ 102.74万
  • 项目类别:
    Research Grant
NSF/BIO-DFG: Biological Fe-S intermediates in the synthesis of nitrogenase metalloclusters
NSF/BIO-DFG:固氮酶金属簇合成中的生物 Fe-S 中间体
  • 批准号:
    2335999
  • 财政年份:
    2024
  • 资助金额:
    $ 102.74万
  • 项目类别:
    Standard Grant
DESIGN: Driving Culture Change in a Federation of Biological Societies via Cohort-Based Early-Career Leaders
设计:通过基于队列的早期职业领袖推动生物协会联盟的文化变革
  • 批准号:
    2334679
  • 财政年份:
    2024
  • 资助金额:
    $ 102.74万
  • 项目类别:
    Standard Grant
Collaborative Research: The Interplay of Water Condensation and Fungal Growth on Biological Surfaces
合作研究:水凝结与生物表面真菌生长的相互作用
  • 批准号:
    2401507
  • 财政年份:
    2024
  • 资助金额:
    $ 102.74万
  • 项目类别:
    Standard Grant
REU Site: Modeling the Dynamics of Biological Systems
REU 网站:生物系统动力学建模
  • 批准号:
    2243955
  • 财政年份:
    2024
  • 资助金额:
    $ 102.74万
  • 项目类别:
    Standard Grant
Collaborative Research: Conference: Large Language Models for Biological Discoveries (LLMs4Bio)
合作研究:会议:生物发现的大型语言模型 (LLMs4Bio)
  • 批准号:
    2411529
  • 财政年份:
    2024
  • 资助金额:
    $ 102.74万
  • 项目类别:
    Standard Grant
Collaborative Research: Conference: Large Language Models for Biological Discoveries (LLMs4Bio)
合作研究:会议:生物发现的大型语言模型 (LLMs4Bio)
  • 批准号:
    2411530
  • 财政年份:
    2024
  • 资助金额:
    $ 102.74万
  • 项目类别:
    Standard Grant
Collaborative Research: NSF-ANR MCB/PHY: Probing Heterogeneity of Biological Systems by Force Spectroscopy
合作研究:NSF-ANR MCB/PHY:通过力谱探测生物系统的异质性
  • 批准号:
    2412551
  • 财政年份:
    2024
  • 资助金额:
    $ 102.74万
  • 项目类别:
    Standard Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了